坦索罗辛治疗男性膀胱过度活动症的探索性分析
本研究为MOTIVE试验中4周坦索罗辛0.4mg导入期的计划探索性分析,纳入116例42-88岁有尿急和尿频(>8次/24小时)的男性退伍军人。结果显示坦索罗辛显著减少排尿频率、尿急评分和夜尿次数,但基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测OAB症状改善。
要点
- 坦索罗辛0.4mg治疗4周可显著减少男性OAB患者的排尿频率、尿急评分和夜尿次数。
- 基线AUA-7 SI总分及排尿症状亚评分类别与AUA-7 SI总分显著降低相关。
- 基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测OAB症状改善。
核心结论
- 短期坦索罗辛治疗与男性OAB症状的统计学显著减少相关。
- 基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测坦索罗辛对OAB症状的改善。
研究设计与样本
- 研究为MOTIVE试验中4周坦索罗辛0.4mg导入期的计划探索性分析。
- 共纳入116例42-88岁有尿急和尿频(>8次/24小时)的男性退伍军人。
主要发现
- 排尿频率从11.3次/24小时降至10.0次/24小时(P<.0001)。
- 尿急评分从平均2.5分降至2.2分(P<.0001)。
- 夜尿次数从2.1次降至1.8次(P<.001)。
- 仅基线AUA-7 SI总分和排尿症状亚评分类别(轻、中、重)与AUA-7 SI总分显著降低相关。
- 连续变量中仅基线AUA-7 SI总分与AUA-7 SI储尿症状变化相关。
关键数值与推荐
- 坦索罗辛剂量为0.4mg,治疗持续4周。
- OAB入选标准为尿急和尿频(>8次排尿/24小时)。
- AUA-7 SI总分及排尿症状亚评分分为轻度、中度、重度三类。
临床怎么用
- 对于男性OAB患者,可考虑短期使用坦索罗辛0.4mg以改善排尿频率、尿急和夜尿。
- 基线残余尿、尿流率和AUA-7排尿症状亚评分不宜用于预测坦索罗辛对OAB症状的疗效。
局限性
- 本研究为探索性分析,结果需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate tamsulosin (α-blocker therapy) for male overactive bladder (OAB) and to examine if indicators of concomitant benign prostatic hyperplasia are associated with OAB symptom improvement. MATERIALS AND METHODS: This was a planned, exploratory analysis of a 4-week, α-blocker (tamsulosin 0.4 mg) run-in phase of the Male Overactive Bladder Trial in Veterans (MOTIVE). Participants with urinary urgency and urinary frequency (> 8 voids/24 hours) completed bladder diaries, answered symptom questionnaires (AUA-7 SI), and had post-void residual and noninvasive uroflowmetry measurement. RESULTS: A total of 116 male Veterans aged 42-88 years with OAB participated. There were statistically significant reductions in voiding frequency (11.3 > 10.0 voids/24 hours, P < .0001), urgency scores (mean 2.5-2.2 points, P < .0001), and nightly nocturia (2.1 > 1.8, P < .001). Only baseline AUA-7 SI total and voiding subscale categories (mild, moderate, severe) were associated with significant reduction in AUA-7 SI total score. For continuous variables, only AUA-7 SI baseline total score was associated with AUA-7 SI storage symptom changes. No other baseline measures were associated with changes in urgency, frequency, or nocturia. CONCLUSION: Initiation of short course tamsulosin therapy in men was associated with statistical reduction in OAB symptoms. Baseline post-void residual, uroflow rate, and the voiding symptom subscore of the AUA-7 SI were not predictive of OAB symptom improvement with tamsulosin. These findings merits further exploration.
引用
- Johnson TM, Goode PS, Hammontree L, et al. An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden. Urology. 2021. PMID: 33482134. doi:10.1016/j.urology.2021.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。